Vice President, Head of Global Regulatory Policy and Strategy
Eli Lilly and Company, United States
JEFF FRANCER serves as Vice President, Head of Global Regulatory Policy and Strategy for Eli Lilly and Company. In this role, Jeff leads Lilly’s U.S. and international regulatory policy and research teams. Jeff is an accomplished legal and regulatory policy advocate with over 20 years of experience leading and advising biopharmaceutical companies and policy makers to craft regulatory systems that best meet the needs of patients and improve public health.
Prior to joining Lilly, Jeff most recently served as Senior Vice President, General Counsel, and Interim CEO of the Association for Accessible Medicines, where he led legal and international trade advocacy for the nation’s leading trade association for biosimilar and generic medicines. From 2007-2016, Jeff served as Vice President and Senior Counsel of the Pharmaceutical Research and Manufacturers of America (PhRMA) where he was the principal counsel to the association on issues relating to the research, development, and regulation of medicines in the U.S. and globally. Prior to joining PhRMA, Jeff served as Associate General Counsel, U.S. Compliance Officer, and Chief Privacy Officer of Biogen Idec, Inc. At Biogen he was the primary in-house counsel on FDA issues, and he led the U.S. corporate compliance program. Prior to his time in industry at Biogen Idec, Jeff served as Associate Chief Counsel of the Food and Drug Administration from 2003 to 2005, where he advised agency leaders on issues including clinical investigation, manufacturing compliance, drug promotion, enforcement, and legislative matters.
Jeff received his A.B. in Public Policy and Economics from Brown University, his M.P.P. from Harvard University, and his J.D. from the University of Virginia. He has served on the Board of Directors of the Food and Drug Law Institute (FDLI) and the Editorial Advisory Board of the Food and Drug Law Journal.
Disclosure information not submitted.
Opening Plenary: Preparing for the Next Round of User Fee Negotiations
Thursday, June 6, 2024
9:00 AM – 10:15 AM EDT